TSX Venture:
QPT
EDMONTON, AB, June 1, 2021 /CNW/ - Quest PharmaTech Inc.
(TSXV: QPT) ("Quest" or the "Company") announces that clinical
investigators working with OncoQuest Pharmaceuticals, Inc. ("OQP")
lead clinical candidate oregovomab, will be making two
presentations as part of the American Society of Clinical Oncology
(ASCO) conference proceedings. OQP acquired oregovomab from
OncoQuest Inc., one of the equity investee companies (45%) of Quest
PharmaTech Inc.
The first presentation by Dr. Angeles
Alvarez Secord, Principal Investigator and Associate
Director of Clinical Research at Duke Cancer Institute of
Duke University will update the
research community on progress with the ongoing FLORA 5 phase III
clinical study of front-line carboplatin-paclitaxel-oregovomab
chemotherapy. This double blind and placebo controlled
multinational trial is currently accruing patients at centers in
the US, Canada, Europe and Asia and is adding additional centers and
participating geographies. This study seeks to confirm the
observations of Brewer et al in Gynecologic Oncology 2020 that
demonstrated how oregovomab in combination with carboplatin and
paclitaxel could dramatically improve both progression free and
overall survival relative to chemotherapy in the absence of
incremental toxicity.
The second oregovomab report at ASCO being presented by Dr.
Robert Holloway, Medical Director of
the Gynecologic Oncology Program at Florida Hospital is an abstract
presentation of the results from the Phase 1b oregovomab clinical trial protocol
ORE-QPT-003H. The report titled, "Final survival follow up
and translational associations using interval indirect immunization
with oregovomab (O) and poly ICLC (Hiltonol®) (H) in patients (pts)
with recurrent platinum resistant ovarian cancer" evaluated
heavily pretreated patients with recurrent ovarian cancer receiving
an indirect immunization with oregovomab in combination with the
TLR3 agonist polyICLC (Hiltonol®). The median OS was 15 months in
this advance disease population and 4 patients remained alive at
the data lock. The study established that Hiltonol® is a suitable
candidate for augmenting immune response in the immune suppressed
heavily advanced disease population and pointed to novel approaches
to the management of this difficult and unmet medical need.
"OQP remains on track for seeking registration of its lead
product oregovomab in the front-line ovarian cancer setting, and
continues to explore optimal combinations with various
immune-adjuvants for the recurrent setting" said Dr. Sunil Gupta MD, FRCPC, Chief Medical Officer of
OncoQuest Pharmaceuticals, Inc. "We are accelerating the enrollment
of the FLORA-5 study as more countries and centers come on
board."
On corporate matters, Quest announces that it will be holding
its annual, general and special meeting of shareholders on
Monday, July 5, 2021 at 11:00 am at the Company's corporate office in
Edmonton. Due to Covid 19 concerns, shareholders are
encouraged to attend remotely. Quest also announces that its annual
audited financial statements and MD&A for the year ended
January 31, 2021 have recently been
filed on SEDAR and can be viewed at www.sedar.com. Lastly, Quest
announces the granting of 1,250,000 stock options to officers, at
an exercise price of $0.115 per
common share, expiring 10 years from the date of grant, subject to
TSX Venture Exchange approval.
About Oregovomab.
Oregovomab is a murine IgG against CA 125. Indirect immunization
with oregovomab interacts with immune modulating properties of
infused paclitaxel and carboplatin resulting in synergistic
clinical benefit as observed in this phase 2 trial. In a
randomized Phase 2 clinical trial of 97 patients, treatment with
Oregovomab demonstrated a highly clinically significant outcome for
both progression-free and overall survival favoring the addition of
oregovomab to a standard of care chemotherapy combination of
carboplatin and paclitaxel. The risk of progression and of death
was reduced by more than 50% when compared to placebo, and safety
data showed that oregovomab did not add incremental toxicity to the
chemotherapy regimen. Clinical and translational results were
published in Gynecology Oncology 2020 156:523-529 and
Cancer Immunology and Immunotherapy 2020 69: 383-397,
respectively.
About OncoQuest Pharmaceuticals Inc.
OncoQuest Pharmaceuticals Inc. is a Korean biopharmaceutical
company focused on the development and commercialization of
immunotherapies for cancer. OncoQuest Pharmaceuticals' technology
platform includes a portfolio of tumor antigen specific monoclonal
immunoglobulins targeting CA-125, MUC1, PSA and Her2/neu. The
company is exploring the therapeutic potential of these antibodies
as indirect immunizers in combination with other immune modulating
drugs or drug combinations to address unmet medical needs in
oncology. To learn more, visit www.oqp.co.kr
About Quest PharmaTech Inc.
Quest PharmaTech Inc is a publicly traded, Canadian based
biopharmaceutical company (TSX-V:QPT) developing products to
improve the quality of life. The company has a 45% ownership
interest in OncoQuest Inc. which sold its immunotherapy technology
to OncoQuest Pharmaceuticals, Inc. Quest also has an equity
interest in OncoVent, a Chinese joint venture developing
antibody-based immunotherapeutic products for cancer for the
Greater China territory. Quest has
an ownership interest in Bioceltran which is focused on SP
Technology™ for transdermal delivery of drugs and photosensitizers
for pharmaceutical and cosmetic purposes. Quest is also developing
the mutant EGF technology licensed from Stanford University for chronic wound healing
applications. Quest, through its ownership interest in
OncoCare Therapeutics, is developing an antibody licensed from
University of Nebraska, AR 9.6 mAb
against truncated O-glycan on MUC16, for targeted cancer therapy
applications. To learn more, visit
www.questpharmatech.com
Forward Looking Statements
This press release
includes forward-looking statements. In some cases, forward-looking
statements can be identified by terminology such as "may,"
"should," "potential," "continue," "expects," "anticipates,"
"intends," "plans," "believes," "estimates," and similar
expressions. These statements are based on management's
expectations and assumptions as of the date of this press release
and are subject to a number of risks and uncertainties, many of
which are difficult to predict that could cause actual results to
differ materially from current expectations and assumptions from
those set forth or implied by any forward-looking
statements. The information in this release is provided only
as of the date of this release and the company undertakes no
obligation to update any forward-looking statements contained in
this release based on new information, future events, or otherwise,
except as required by law.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View original
content:http://www.prnewswire.com/news-releases/quest-pharmatech-announces-two-presentations-by-oncoquest-pharmaceuticals-inc-at-the-2021-annual-meeting-of-the-american-association-of-clinical-oncologists-301303237.html
SOURCE Quest PharmaTech Inc.
